Aimmune Therapeutics is set to present new data on its AR101 compound, Palforzia, a potential new treatment for peanut allergies, in early November 2019 at the American College of Asthma, Allergy, and Immunology (ACAAI) annual meeting.
Palforzia is an emerging oral immunotherapy that’s designed to “reduce the frequency and severity of allergic reactions to accidental peanut exposure,” and is currently being reviewed by the U.S. Food and Drug Administration.
The chief medical officer of Aimmune, Daniel Adelman, MD, has said the following regarding the upcoming presentation: “We’re pleased to be presenting a robust and diverse set of studies related to peanut allergy, ranging from its diagnosis, associated costs and effects on quality of life, to patient selection and integration of potential treatments in clinical practice…The progress we and others have made on behalf of patients and families affected by living with peanut allergies in just the past 12 months has been inspiring and we look forward to learning about additional important advances at this year’s ACAAI meeting.”
The presentation at ACAAI 2019 will cover data from Aimmune’s ARTEMIS and PALISADE studies.
If Palforzia is approved, it could provide a new option for patients with this life-threatening allergy.